Total number of voting rights and capital on January 31, 2024

         Total number of voting rights and capital on January 31, 2024January 31, 2024Company announcement No. 05  Referring to company announcement 02, on January 29, 2024, where Novozymes A/S ("Novozymes") announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292...
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

        

Total number of voting rights and capital on January 31, 2024




January 31, 2024
Company announcement No. 05
 


Referring to company announcement 02, on January 29, 2024, where Novozymes A/S ("Novozymes") announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292 through the issuance of a total of 187,298,646 new Novozymes B-shares in the denomination of DKK 2 each.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act, it is hereby announced that the total share capital as of today consists of nominally DKK 936,597,292 comprising a total of 468,298,646 shares, divided into 53,743,600 A shares and 414,555,046 B shares with a nominal value of DKK 2 each and a total of 1,903,982,092 voting rights.

  Nominal Value, DKK Number of shares
A shares 107,487,200 53,743,600
B shares 829,110,092 414,555,046
Total 936,597,292 468,298,646


Contact information
Investor Relations    
Tobias Bjorklund +45 3077 8682 tobb@novonesis.com
Anders Enevoldsen +45 5350 1453 adev@novonesis.com


Media Relations
   
Lina Danstrup +45 3077 0552 lind@novonesis.com

     


 

Attachment

  • 2024_05_Total_Number_Of_Voting_Rights_And_Capital

Per maggiori informazioni
Sito Web
novozymes.com

Ufficio Stampa

 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti

Allegati
Slide ShowSlide Show
Non disponibili
;